Ursodeoxycholic Acid in Patients With Chronic Heart Failure: A Double-Blind, Randomized, Placebo-Controlled, Crossover Trial

von Haehling, Stephan, Schefold, Joerg C., Jankowska, Ewa A., Springer, Jochen, Vazir, Ali, Kalra, Paul R., Sandek, Anja, Fauler, Günter, Stojakovic, Tatjana, Trauner, Michael, Ponikowski, Piotr, Volk, Hans-Dieter, Doehner, Wolfram, Coats, Andrew J., Poole-Wilson, Philip A. and Anker, Stefan D. (2012) Ursodeoxycholic Acid in Patients With Chronic Heart Failure: A Double-Blind, Randomized, Placebo-Controlled, Crossover Trial. Journal of the American College of Cardiology, 59 (6). pp. 585-592. ISSN 0735-1097

Full text not available from this repository.

Abstract

Objectives: This study sought to assess the effects of ursodeoxycholic acid (UDCA) on endothelial function and inflammatory markers in patients with chronic heart failure (CHF). Background: Endothelial dysfunction is commonly observed in patients with CHF, and it contributes to the limitation in exercise capacity that accompanies this condition. Bacterial lipopolysaccharide may trigger proinflammatory cytokine release and promote further endothelial dysfunction. UDCA, a bile acid used in the treatment of cholestatic liver disease, has anti-inflammatory and cytoprotective properties and may contribute to the formation of mixed micelles around lipopolysaccharide. These properties may help to improve peripheral blood flow in patients with CHF.MethodsWe performed a prospective, single-center, double-blind, randomized, placebo-controlled crossover study of UDCA in 17 clinically stable male patients with CHF (New York Heart Association functional class II/III, left ventricular ejection fraction

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User:	Rhiannon Harvey
Date Deposited:	29 Feb 2012 14:05
Last Modified:	23 Oct 2022 00:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/37679
DOI:	10.1016/j.jacc.2011.10.880

Actions (login required)

View Item